🔴 Precigen is trading 10.56% down today amid broader technology-led selling and biotech weakness

Precigen is trading at $6.43, down 10.56%, amid broader technology-led selling and biotech weakness, with no verified company-specific catalyst.

• No verified new company-specific announcement was found to explain the October 16 decline; a report tracking the move also noted no new company catalyst.
• A Precigen conference appearance discussed its existing therapy and platform.
• In the supplied market context, the Nasdaq fell 2.21%, the S&P 500 1.24%, and biotech ETF XBI 2.06%.